Boston

Epidemiological Brief

As of 27 July 2026, Boston is classified at LOW epidemic risk (composite score 18.9). Influenza-like illness is the most prominent signal, with an ILI prevalence of 7.7% — 31% of the seasonal reference peak — representing sustained summer influenza activity well above typical mid-year baseline levels. Pertussis incidence stands at 1.0 case per 100,000, and measles incidence is low at 0.15 cases per 100,000. COVID-19 activity is low at 0.13 cases per 100,000. Mpox is detected at 0.07 cases per 100,000, with an attenuated adjusted impact. Travel-associated dengue cases are present at 0.17 cases per 100,000, representing imported infections with no local vector competence. Wastewater-based epidemiology (ATCP-73RE) is actively monitoring COVID-19 and influenza signals. International arrivals number 130. Conditions are mild (18 °C, 70% humidity, no precipitation), unremarkable from a vector-borne risk standpoint. Recommended public health measures include maintaining influenza rapid testing at fan medical posts, monitoring for pertussis clusters through Massachusetts disease reporting systems, verifying MMR vaccination status for incoming international travellers, maintaining mpox clinical screening pathways, and issuing standard traveller health advisories covering influenza, dengue prevention, and respiratory hygiene throughout the tournament period.

Model SCEME v3.1 · Updated July 27, 2026

Please consult a local doctor or pharmacist for guidance and medication.